Education
About Us
Working with TipRanks
Follow Us
Urteste S.A. (PL:URT)
:URT
URT Stock Chart & Stats
Day’s Range― - ―
52-Week Rangezł37.00 - zł106.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)330.00
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)zł3.79M
Total Debt (Recent Filing)zł355.00K
Price to Earnings (P/E)―
Beta0.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,409,669
10 Day Avg. Volume615
30 Day Avg. Volume330
Financial Highlights & Ratios
PEG Ratio0.92
Price to Book (P/B)5.57
Price to Sales (P/S)74.56
P/FCF Ratio-9.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
URT FAQ
What was Urteste S.A.’s price range in the past 12 months?
Urteste S.A. lowest stock price was zł37.00 and its highest was zł106.00 in the past 12 months.
What is Urteste S.A.’s market cap?
Currently, no data Available
When is Urteste S.A.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Urteste S.A.’s earnings last quarter?
Currently, no data Available
Is Urteste S.A. overvalued?
According to Wall Street analysts Urteste S.A.’s price is currently Overvalued.
Does Urteste S.A. pay dividends?
Urteste S.A. does not currently pay dividends.
What is Urteste S.A.’s EPS estimate?
Urteste S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Urteste S.A. have?
Urteste S.A. has 1,409,669 shares outstanding.
What happened to Urteste S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Urteste S.A.?
Currently, no hedge funds are holding shares in PL:URT
Company Description
Urteste S.A.
Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, stomach, lung, oesophagus, ovary, endometrium, blood, breast, and nervous system cancer. The company was incorporated in 2021 and is based in Gdansk, Poland.
Technical Analysis
―
Ryvu Therapeutics SA
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―
Mabion SA
―